Updates are available Correction dated 2025-04-26
Click to view Correction: https://doi.org/10.1007/s11357-025-01617-6
-
Authors
Mentink, Lara J. https://orcid.org/0000-0003-4373-7910
van Osch, Matthias J. P.
Bakker, Leanne J.
Olde Rikkert, Marcel G. M.
Beckmann, Christian F.
Claassen, Jurgen A. H. R.
Haak, Koen V.
-
Funding
Funding for this research was provided by:
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (17854)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (012-200-013)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (016.160.351)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (09150171910043)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (016.Veni.171.068)
Alzheimer Nederland (WE.05-2010-04)
Wellcome Trust (215573/Z/19/Z)
- License Information
-
More Information
Article History
Received: 29 August 2024
Accepted: 26 October 2024
First Online: 12 November 2024
Change Date: 26 April 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s11357-025-01617-6
Declarations
:
: The SCHIP study was approved by the institutional review board (CMO, Commissie Mensgebonden Onderzoek, Region Arnhem-Nijmegen, NL55712.091.16, file number 2016–2337) and performed in accordance with good clinical practice guidelines and the world medical associations code of ethics (Declaration of Helsinki).
: Written informed consent was obtained from all participants after they received detailed study information. Participants received a stipend of 50 euros for participating.
: CFB is founder and shareholder of SBGneuro Ltd.
